Cambridge Healthtech Institute’s 3rd Annual

Combination Cancer Immunotherapy

Rational Combination Strategies to Improve Efficacy and Reduce Resistance

June 18-19, 2019

 

The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to deliver long-term survival benefits that may be unavailable with current approaches. CHI’s 3rd Annual Combination Cancer Immunotherapy conference will explore the most effective combinations of immunotherapy with conventional cancer therapy, other immunotherapy, or targeted therapy. Coverage will include understanding the mechanism of action, managing toxicity, strategies to design synergistic combinations, biomarker development and case studies of ongoing combination immunotherapy studies from the leading researchers in industry and academia.

Final Agenda

Stay on to attend Wednesday, June 19 - Thursday, June 20

Small Molecules for Immuno-Oncology Therapeutics

Recommended Short Course

SC10: In vitro and in vivo Modeling for Cancer Immunotherapy

Tuesday, June 18

7:00 am Registration Open and Morning Coffee

RATIONAL COMBINATION CANCER IMMUNOTHERAPY

8:00 Chairperson’s Remarks

Rakesh Dixit, PhD, DABT, Vice President, R&D; Global Head Biologics Safety Assessment, MedImmune


8:10 KEYNOTE PRESENTATION: Immunotherapy Combinations: Friends or Foes

Rakesh Dixit, PhD, DABT, Vice President, R&D; Global Head Biologics Safety Assessment, MedImmune

This presentation will cover: 1) similarities and differences in outcome of immune activation with antagonists vs. agonists/combinations, etc.; 2) strategies for inducing immunologically hot vs. cold tumors; 3) single agents vs. combinations: pros and cons; 4) personalized medicine approaches to immune-oncology; 5) a case of unique bispecific of anti-PD-1:CTA4 with a potential for better TI than combination.

8:40 Drivers in the Clinical Development of Cancer Combination Therapies

Emmett Schmidt, PhD, Distinguished Scientist & Executive Director, Merck Research Labs

More than 3,000 clinical trials are evaluating the clinical activity of the PD-1/PD-L1 checkpoint inhibitors as monotherapies and in combination with other cancer therapies. The PD-1/PD-L1 checkpoint inhibitors are remarkable for their clinical activities in shrinking tumors across a wide range of tumor types, in causing durable responses, and in their tolerability. These attributes position them as favorable agents in clinical combinations. Dr. Schmidt will update the current landscape of emerging results of PD-1 checkpoint inhibitor combinations and consider potential options for “Bedside to Bench” translation.

9:10 T Cell Dysfunction in Cancer and Combination Immunotherapy

Dimitris Skokos, PhD, Associate Director, Immune & Inflammatory Diseases, Regeneron Pharmaceuticals

Most patients with cancer do not develop durable antitumor responses after programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) checkpoint inhibition monotherapy because of an ephemeral reversal of T cell dysfunction and failure to promote long-lasting immunological T cell memory. Activating costimulatory pathways to induce stronger T cell activation may improve the efficacy of checkpoint inhibition and lead to durable antitumor responses.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

EMERGING MODALITIES FOR COMBINATION IMMUNOTHERAPY

10:25 KEYNOTE PRESENTATION: PD-1 Antibody Is Foundational Anti-Cancer Therapy Both as Single Agent and with Additional Modalities

Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

PD-1 antibodies have shown important therapeutic activity and clinically meaningful benefit across a number of major cancer types and lines of treatment as monotherapy. Precision medicine tools have enriched for monotherapy activity, identified potential resistance biology and provided rationale for modalities to be explored as combination partners. Certain combinations have demonstrated clinically meaningful therapeutic benefit.

10:55 Combinatorial Treatment with Oncolytic Adenovirotherapy and CAR T Cell Therapy for Solid Tumor Treatment

Masataka Suzuki, PhD, Assistant Professor, Center for Cell & Gene Therapy, Baylor College of Medicine

This presentation will cover: 1) Local treatment of oncolytic adenovirus is safe but is insufficient to eradicate advanced/metastasized tumors; 2) Successful CAR T cell therapy for solid tumors needs to overcome multiple barriers; 3) Combination with oncolytic adenovirus and CAR T cell overcomes the inherent limitations of each agent.

11:25 Sponsored Presentation (Opportunity Available)

11:55 Transition to Lunch

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Session Break

EMERGING MODALITIES FOR COMBINATION IMMUNOTHERAPY (CONT.)

1:05 Chairperson’s Remarks

Mark C. Poznansky, MD, PhD, Director, Vaccine & Immunotherapy Center, Massachusetts General Hospital; Associate Professor, Harvard Medical School

1:10 Reversing Resistance to Definitive Anti-PD-1 Failures with Intratumoral IL-12 and Pembrolizumab Combination Therapy

Chris Twitty, PhD, CSO, OncoSec

This talk will discuss approaches to overcome immune resistance mechanisms in cancer, namely by reinvigorating T cell exhaustion with engineered cytokines, checkpoint bispecifics and T cell engaging CD3 bispecifics.

1:40 Development of Novel Combination Immunotherapies for Ovarian Cancer and Mesothelioma

Mark C. Poznansky, MD, PhD, Director, Vaccine & Immunotherapy Center, Massachusetts General Hospital; Associate Professor, Harvard Medical School

Ovarian cancer and mesothelioma are considered immunogenic tumors and yet the impact of immunotherapy on these diseases has been limited. We set out to design novel combination immune therapies that both reverse the immune suppressive intratumoral microenvironment while arming and activating the tumor antigen specific T cell response against the cancer. We will present preclinical data in immune competent syngeneic and orthotopic mouse models that support our combinatorial approach.

2:10 Sponsored Presentation (Opportunity Available)

2:25 Refreshment Break in the Exhibit Hall with Poster Viewing

IO PLENARY SESSION: PARTNERING ECOSYSTEM

3:10 PANEL DISCUSSION: Partnering, Preclinical Strategies and Tools, IO Clinical Trials; Capital Invested in IO Relative to Other Oncology Areas

Zawel_LeighModerator: Leigh Zawel, PhD, CSO, Cullinan Oncology


Panelists:

Woo_MichaelMichael Woo, PhD, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.


Williams_SybilSybil Williams, PhD, Director, Biology Oncology Discovery, Merck


Young_PaulPaul Young, PhD, Executive Director, Business Development & Licensing, Merck


Godec_JernejJernej Godec, PhD, Associate, Apple Tree Partners


Adam_StaceyStacey J. Adam, PhD, Director, Cancer Research Partnerships, Foundation for the National Institutes of Health


  • Has the IO bubble popped? Why have no other IO drugs emerged with PD1/PDL1-like efficacy?
  • What combination strategies are being explored to convert poorly PD1 responsive tumors to more responsive ones?
  • Are there new IO monotherapies or combo’s that appear promising?
  • Is patient stratification practical with IO therapies?
  • What partnering strategies are most effective?
  • What is a recent deal your firm signed that you’re excited about?

4:10 Transition to Keynote


4:20 PLENARY KEYNOTE SESSION

5:20 Welcome Reception in the Exhibit Hall with Poster Viewing

6:35 Find Your Table, Meet Your Moderator

6:40 Breakout Discussion Groups

7:30 Close of Day

Wednesday, June 19

7:00 am Registration Open and Morning Coffee

BISPECIFIC ANTIBODIES FOR COMBINATION IMMUNOTHERAPY

8:00 Chairperson’s Remarks

Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor

8:05 Bispecifics to the Rescue: Enabling T Cell Activation in Immune Deserts

Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor

This talk will discuss approaches to overcome immune resistance mechanisms in cancer, namely by reinvigorating exhausted T cells by treatment with engineered cytokines, checkpoint bispecifics and/or T cell engaging CD3 bispecifics.

8:35 Bispecific T Cell Engagers (BiTEs®) in Multiple Myeloma

Francesco Galimi, MD, PhD, Global Product General Manager, Early Development, Amgen

The bispecific T cell engager (BiTE®) blinatumomab (Blincyto®) has recently been approved for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Based on the potent anti-tumor activity of Blincyto® in B-cell malignancies, BiTE® antibody constructs directed against other target antigens are being tested in a number of malignancies, in particular acute myeloid leukemia and multiple myeloma. We will review ongoing activities in this field.

9:05 Sponsored Presentation (Opportunity Available)

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

EMERGING TARGETS FOR COMBINATION IMMUNOTHERAPY

10:20 Understanding Immune Checkpoint TIM-3 Biology and Anti-TIM-3 Antibody for Cancer Immunotherapy

Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research

TIM-3 has critical roles in tumor-induced immune suppression. Blockade of TIM-3, alone or in combination with PD-1 pathway blockade, has shown anti-tumor efficacy in several preclinical cancer models. TIM-3/PD-1 pathway co-blockade to activate immune response and control tumor growth could reflect the combined effects on modulating not only the functional phenotype of dysfunctional effector T cells, but also inhibiting the suppressive activity of various suppressor cells.

10:50 Rational Combinations with an ICOS Agonist Based on Reverse Translational Biomarker Analysis

Elizabeth Trehu, MD, CMO, Jounce Therapeutics

Inducible T cell Co-stimulator (ICOS) is a costimulatory molecule expressed on T cells upon activation. JTX-2011 is an ICOS agonist with a primary mechanism of action of activation and proliferation of primed CD4 T effector cells. Peripheral blood and tumor biomarkers collected in ICONIC, the first-in-human clinical trial of JTX-2011, have produced new insights into the mechanism of action and have informed combination strategies for future development.

11:20 Supercharging the Tumor Microenvironment with the Engineered Cytokines NKTR-214 and KNTR-255

Steve Doberstein, PhD, CSO & Senior Vice President, Research, Nektar Therapeutics

This presentation will cover: 1) the idea of combining the immune-modulating properties of checkpoint inhibitors and other immunological medicines with the immune-stimulating function of engineered cytokines being conceptually powerful; 2) engineered cytokines can more effectively stimulate cytokine receptor pathways, while controlling adverse events; 3) the combination of NKTR-214 with Opdivo has demonstrated powerful anti-tumor effects and profoundly alters the tumor microenviroment, increasing effector T cell counts, increasing PD-1 expression on tumor T cells, and converting PD-L1 negative tumors to positive, while maintaining a more tolerable AE profile than traditional cytokine therapies.

11:50 Transition to Lunch

12:00 pm Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Transition to Plenary


12:50 PLENARY KEYNOTE SESSION

2:20 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing

3:05 Close of Conference

Stay on to attend Wednesday, June 19 - Thursday, June 20

Small Molecules for Immuno-Oncology Therapeutics

Recommended Short Course

SC10: In vitro and in vivo Modeling for Cancer Immunotherapy